Parison Amy 4
4 · Editas Medicine, Inc. · Filed Jun 5, 2026
Research Summary
AI-generated summary of this filing
Editas (EDIT) CFO Amy Parison Sells 464 Shares
What Happened
Amy Parison, Chief Financial Officer of Editas Medicine (EDIT), sold 464 shares on June 3, 2026 in a transaction totaling about $1,253. The reported weighted-average price was $2.70 per share. This was a sale (not a purchase) and appears to be a routine disposition to satisfy tax obligations, not a discretionary trade.
Key Details
- Transaction date: June 3, 2026; Form 4 filed June 5, 2026. No indication in the provided data that the filing was late.
- Price: weighted average $2.70; executed in multiple trades at $2.7010–$2.7049 (report reflects weighted average).
- Shares disposed: 464; proceeds ≈ $1,253.
- Footnote: Sale was effected under a durable automatic sales instruction plan adopted July 7, 2022, to cover tax withholding for restricted stock units that vested on June 2, 2026; sale was not a discretionary trade by the reporting person. Reporting person offers to provide full trade-by-trade details on request.
- Shares owned after transaction: not disclosed in the provided filing.
Context
This sale was executed to meet tax withholding on RSU vesting and was automated (non-discretionary), a common reason for small insider sales that does not necessarily indicate a change in insider sentiment. For retail investors, purchases by insiders typically carry more signaling weight than routine tax-withholding sales.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-06-03$2.70/sh−464$1,253→ 14,970 total
Footnotes (2)
- [F1]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on July 7, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2026. The sale does not represent a discretionary trade by the Reporting Person.
- [F2]This transaction was executed in multiple trades at prices ranging from $2.7010 to $2.7049. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.